These ASX 200 shares could rise 30% to 40%

Let's see what analysts are saying about these buy-rated shares.

| More on:
Person pointing finger on on an increasing graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are on the hunt for big returns for your investment portfolio, then keep reading.

That's because listed below are two ASX 200 shares that have been named as buys and tipped to rise over 30% from current levels.

Here's why brokers are bullish on these big names:

Mineral Resources Ltd (ASX: MIN)

Bell Potter thinks that this mining and mining services company's shares are dirt cheap despite a strong rebound this week.

In response to Mineral Resources' quarterly update, the broker has reaffirmed its buy rating on the ASX 200 share with an improved price target of $29.50. Based on its current share price of $20.50, this implies potential upside of 44% for investors over the next 12 months.

Commenting on its buy recommendation, the broker said:

We maintain our Buy recommendation on valuation grounds. We continue to hold the view that (1) Onslow will be commissioned successfully, (2) associated Iron Ore & Services volumes will enable deleveraging of the balance sheet, (3) MIN has other options to manage its debt, including re-financing, and further asset sell downs, and (4) MIN's deleveraging will co-inside with it addressing its leadership and governance issues. Our Target Price is most sensitive to iron ore price. Long-term we apply US$95/t (62% CIF) vs the current spot of ~US$99/t. We share the view that iron ore will continue to see support in the US$80/t – US$100/t range.

ResMed Inc. (ASX: RMD)

Analysts at Goldman Sachs continue to believe that this sleep disorder treatment company's shares are being undervalued by the market.

The broker was pleased with ResMed's performance during the third quarter and particularly its gross margin improvement.

In response, Goldman reiterated its conviction buy rating on the ASX 200 share with an improved price target of $49.30. Based on its current share price of $36.77, this suggests that upside of 34% is possible for investors over the next 12 months.

Its analysts are bullish due to ResMed's strong growth outlook and the "unjustified" low multiples its shares trade on. It said:

RMD is the world's leading CPAP manufacturer of devices and masks in the treatment of OSA. The company has expanded to providing software services to out of hospital healthcare providers including Durable Equipment Manufacturers (DMEs), nursing homes and home health and hospice agencies. Our Buy recommendation on RMD is premised on (1) Ongoing robust new patient growth for CPAP therapy despite the market entry of GLP-1 drugs to treat OSA, (2) Further RMD market share gains, building on its #1 global market position, (3) Expansion of the OSA market in regions outside of the US. We believe the stock's current trading multiple is unjustified based on its growth outlook.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

Take your profits and run! Brokers say sell these 3 ASX 200 shares

Experts say these ASX 200 stocks are trading at high share prices with limited upside potential from here.

Read more »

Person handing out $50 notes, symbolising ex-dividend date.
Broker Notes

Where to invest $20,000 into ASX 200 shares

Brokers think these shares could be top picks for Aussie investors.

Read more »

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why Macquarie expects this ASX 200 dividend stock to keep outperforming

Macquarie has tipped this ASX 200 dividend stock to outperform. Let’s find out why.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »